TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01778855

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV t-PA and normothermia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IV-tPA and hypothermia
Study: NCT04618523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine
Description: Artemisinin-based combination treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Artemisinin-based combination treatment
Study: NCT03602378

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary cortisol
Description: 5 samples of saliva (first sample before around 22:00 and other samples the next morning, after awakening (00, 15, 30 and 60 minutes).

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary cortisol
Description: 5 samples of saliva (first sample before around 22:00 and other samples the next morning, after awakening (00, 15, 30 and 60 minutes).

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary cortisol
Description: 5 samples of saliva (first sample before around 22:00 and other samples the next morning, after awakening (00, 15, 30 and 60 minutes).

Intervention type: DEVICE
Intervention: Holter Medilog AR12 Plus
Description: Holter Medilog AR12 Plus - electrocardiogram during 5 minutes for measuring HRV

Intervention type: DEVICE
Intervention: Holter Medilog AR12 Plus
Description: Holter Medilog AR12 Plus - electrocardiogram during 5 minutes for measuring HRV

Intervention type: DEVICE
Intervention: Holter Medilog AR12 Plus
Description: Holter Medilog AR12 Plus - electrocardiogram during 5 minutes for measuring HRV

Intervention type: DEVICE
Intervention: Polar V800
Description: Polar V800 with sensor - during 5 minutes for measuring HRV

Intervention type: DEVICE
Intervention: Polar V800
Description: Polar V800 with sensor - during 5 minutes for measuring HRV

Intervention type: DEVICE
Intervention: Polar V800
Description: Polar V800 with sensor - during 5 minutes for measuring HRV

Intervention type: DEVICE
Intervention: AGE reader
Description: for measuring Advanced Glycation End products (AGEs)

Intervention type: DEVICE
Intervention: AGE reader
Description: for measuring Advanced Glycation End products (AGEs)

Intervention type: DEVICE
Intervention: AGE reader
Description: for measuring Advanced Glycation End products (AGEs)
Study: NCT02069015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Patient education on hypertension delivered through a touchscreen kiosk.
Study: NCT01119859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: The maximum dose was 800 mg for patients weighing more than 100 kg. Tocilizumab was infused into an arm vein over a 1-hour period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to tocilizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to adalimumab
Study: NCT01585974

Intervention type: OTHER
Intervention: No intervention
Description: All dosage, frequency and duration for drugs will be under the decision of the treating physician
Study: NCT01131169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan, melphalan and fludarabine
Description: Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is \> 125% ideal body weight and should be calculated on adjusted ideal body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan, melphalan and fludarabine
Description: Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is \> 125% ideal body weight and should be calculated on adjusted ideal body weight.
Study: NCT00722137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab 375 mg/m^2
Description: Intravenous rituximab 375 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m^2
Description: Intravenous rituximab 375 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide 750 mg/m^2
Description: Intravenous cyclophosphamide 750 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 750 mg/m^2
Description: Intravenous cyclophosphamide 750 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin 50 mg/m^2
Description: Intravenous doxorubicin 50 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m^2
Description: Intravenous doxorubicin 50 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE 1.3 mg/m^2
Description: Intravenous VELCADE 1.3 mg/m\^2 on Days 1,4,8, and 11of a 21-day (3 week) cycle for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone 100 mg/m^2
Description: Oral prednisone 100 mg/m\^2 on Day 1 to Day 5 of a 21-day (3 week) cycle for 6 cycles
Study: NCT02966574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body MRI
Description: The examination will be conducted in the pretreatment assessment of breast cancers with a high metastasis risk and in the monitoring of metastatic breast cancers. The examination is performed without intravenous injection of contrast medium, from the top of the skull to mid-thigh using diffusion weighted sequences in the axial plane, T1-weighted sequences in the coronal plane, STIR T2 weighted sequences in the coronal plane and T1-weighted sequences in the sagittal plane on the spine. Total examination duration is one hour. The interpretation of the results is made by two independent reporters with a complementary expertise, according to a systematic lecture grid.
Study: NCT00722137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 100 mg/m^2
Description: Oral prednisone 100 mg/m\^2 on Day 1 to Day 5 of a 21-day (3 week) cycle for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine 1.4 mg/m^2
Description: Intravenous vincristine 1.4 mg/m\^2 on Day 1of a 21-day (3 week) cycle for 6 cycles. Maximum of 2 mg. Participants could receive 8 cycles if a response was initially documented at the Cycle 6 assessment.
Study: NCT03033589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine 0.25 % Injectable Solution
Description: For the adductor canal block, 20 mL of 0.25% marcaine will be injected with the use of ultrasound guidance into the adductor canal by the attending anesthesiologist on the case in the pre-op holding area.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine 0.25 % Injectable Solution
Description: For the femoral nerve block, 30 mL of 0.25% marcaine will be injected with the use of ultrasound guidance around the femoral nerve sheath by the attending anesthesiologist on the case in the pre-op holding area.
Study: NCT01455441

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training and liraglutide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Training and placebo
Study: NCT02574923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Mononuclear Cells
Description: Transplantation of Autologous Bone Marrow Mononuclear Cells
Study: NCT05209113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: A self-management module was applied to the study group. This module includes informing the patient verbally and in writing about MS disease, the importance of drug compliance, and monitoring of disease symptoms.
Study: NCT00819182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paced respiration
Description: Breathing exercise

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham comparator: fast shallow breathing
Description: sham breathing exercise
Study: NCT00782613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4,4-dimethyl-benziso-2H-selenazine
Description: ALT-2074 in a 0.5% cream formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in a cream formulation
Study: NCT06350019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Penile revascularızation
Description: The importance of resistive index in the preoperative evaluation of vascular-induced erectile dysfunction, predicting the success of penile revascularization surgery, and postoperative patient management was investigated.
Study: NCT02408614

Intervention type: OTHER
Intervention: Slow-paced walking
Description: Subjects will complete 47 minutes of walking on a treadmill at a slow-pace.
Study: NCT00572247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychiatric Rehabilitation Approach to Weight Loss
Description: The use of psychiatric rehabilitation as a way to lose weight
Study: NCT04278365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive affect training
Description: Behavioral training involving position emotion enhancement
Study: NCT03538522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-831(Traneurocin) 10 mg QD
Description: Oral administration of 10 mg capsule of NA-831 QD for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NA-831 (Traneurocin) 20 mg QD
Description: Oral administration of 20 mg capsule of NA-831 QD for 24 weeks
Study: NCT02408614

Intervention type: OTHER
Intervention: Moderate-paced walking
Description: Subjects will complete 47 minutes of walking on a treadmill at a moderate pace.

Intervention type: OTHER
Intervention: Interval Training
Description: Subjects will complete 40 minutes of walking on the treadmill alternating between a moderate and a fast pace.

Intervention type: DEVICE
Intervention: Treadmill

Intervention type: DEVICE
Intervention: Treadmill

Intervention type: DEVICE
Intervention: Treadmill
Study: NCT03538522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NA-831 (Traneurocin) 40 mg QD
Description: Oral administration of 40 mg capsule of NA-831 QD or for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule QD
Description: Oral administration of oral placebo capsule QD or 24 weeks
Study: NCT01010230

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMHF mechanical stimulation active device
Description: Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: LMHF mechanical stimulation placebo device
Description: Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention.
Study: NCT00896701

Intervention type: OTHER
Intervention: flow cytometry

Intervention type: OTHER
Intervention: immunologic technique
Study: NCT04251468

Intervention type: DEVICE
Group type: OTHER
Intervention: GEPII
Description: Saliva probes (K+Sa) will be measured using genetically encoded potassium ion indicators (GEPIIs)

Intervention type: DEVICE
Group type: OTHER
Intervention: Ion-selective electrodes
Description: Plasma potassium levels (K+Pl) will be measured using standard ion-selective electrodes.
Study: NCT02552836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: A 12-week intervention that focuses on resolving interpersonal stressors that are linked to the onset, maintenance or exacerbation of depressive symptoms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy
Description: A 12-week intervention that focuses on non-specific factors that contribute to therapy outcome
Study: NCT03841786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphorus-supplemented study diet
Description: Participants will be instructed to consume a normal diet and will take a total of 1,000 mg of supplemental phosphorus per day in the form of neutral sodium phosphorus (K-Phos neutral®) for 1 week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Diet
Description: Participants will be asked to consume a normal diet supplemented with sodium and potassium chloride tablets commensurate with the extra sodium and potassium content consumed during the study diet period for 1 week
Study: NCT03786783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT02236299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right Coronary Artery Percutaneous Coronary Intervention

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Right Coronary Artery Percutaneous Coronary Intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo infusion
Description: 30 minute placebo infusion used as a comparator to the GLP-1 infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-1 Infusion
Description: 30 minute infusion GLP-1
Study: NCT03966027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative protocol (Immediate weight bearing)
Description: After ORIF of the ankle fracture, the patient will be randomized to follow an immediate weight bearing rehabilitation protocol using an offloading hindfoot brace

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative Protocol (Delayed Weight Bearing)
Description: After ORIF of the ankle fracture, the patient will be randomized to follow a standard delayed weight-bearing rehabilitation protocol
Study: NCT03171233

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization with movement
Description: Participants Mobilization Group with Movement are positioned knee facing the physiotherapist, are not elastic passages above the participant's malleolus and are from the physiotherapist's pelvis. The therapist applies a posterolateral slip sustained to a tibia through the belt, leaning backward, while the talus and forefoot are secured with the space between the thumb and the second finger of the hand of both hands. The participant will be instructed to perform a slow dorsiflexion movement for their maximum amplitude.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self mobilization with movement
Description: In the Auto Mobilization with Movement group, participants will self-mobilize the ankle on top of a box (15 centimeters with a 10 ° incline), a non-elastic band will pass below the malleoli and the back of the band will be placed in the middle of the other Lower limb, thus mobilizing the talus in the posteroinferior direction, the participant should maintain the force in that direction while making the dorsiflexion movement in closed kinetic chain until returning to the initial position again. Using the same group protocol as the therapist will help.
Study: NCT00588042

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood pressure cuff
Description: Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: blood pressure cuff
Description: 3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
Study: NCT02780037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regulatory frame: prevention
Description: Exercise program presented as preventing deterioration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regulatory frame: promotion
Description: Exercise program presented as promoting improvement.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Regulatory frame: not implied
Description: Exercise program presented without implied consequences.
Study: NCT02629315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carnoy's solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10% neutral buffered formaldehyde
Study: NCT01082328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan®
Description: Kuvan® (sapropterin dihydrochloride) oral solution 20 milligram per kilogram (mg/kg) will be given once daily for 28 +/- 1 days.
Study: NCT03131752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elastic Resistance Intervention in Exacerbated Patients
Description: The intervention protocol will performed during 7 days for all patients and this will begin 24 -48 hours after the start of medication for exacerbation. Those who are hospitalized and discharged before this period will continue their treatment at the Laboratory of Spirometry and Respiratory Physiotherapy (LEFIR) of the Federal University of São Carlos. The intervention will also perform for at least 5 continuous days. The ideal elastic band for the training will be chosen through the test of 10 maximum repetitions. The test and the training will be performed in an ergonomic chair allowing the lower limbs to remain pending. After 24 hours of the test, patients will perform knee extension exercise with the appropriate elastic band. Three sets of 10 repetitions will be done in each exercise, with a minimum rest interval of 1 minute between sets or until heart rate values return to baseline. Patients will be re-evaluated 1 and 3 months after the first contact.
Study: NCT00857675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAAA
Description: Adefovir Dipivoxil (12 weeks) + open lable Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAPA
Description: Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + placebo (12 weeks) + open label-Adefovir Dipivoxil (52-260 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AAPA
Description: Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + placebo (12 weeks) + open label-Adefovir Dipivoxil (52-260 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAAA
Description: Placebo (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PAAA
Description: Placebo (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260 weeks)
Study: NCT02699346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000 recording
Study: NCT04095377

Intervention type: OTHER
Intervention: No intervention, this is a retrospective study.
Description: No intervention, this is a retrospective study.
Study: NCT00896701

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study: NCT00842088

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule. Administered orally once a day on dosing days.
Study: NCT03649568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pork
Description: 1 oz lean pork

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Egg
Description: 1 large whole egg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black beans
Description: 0.5 cups cooked black beans

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almonds
Description: 1 oz almonds